CSF2 and melanoma: Talimogene laherparepvec (T-Vec, ImlygicTM formerly OncovexGM-CSF), an HSV-1 virus encoding granulocyte macrophage colony-stimulating factor (GM-CSF), was the first OV approved by the US Food and Drug Administration for the treatment of melanoma (5).